UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
Dated
September
2, 2015
Commission
File Number 001-36421
AURINIA PHARMACEUTICALS INC.
(Exact
name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s Name)
#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250)
708-4272
(Address and telephone number of registrant’s
principle executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ⃞ Form 40-F ⊠
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ⃞
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ⃞ No ⊠
If "Yes" is
marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: |
September 2, 2015 |
|||
Aurinia Pharmaceuticals Inc. |
||||
|
||||
|
|
By: |
/s/ Michael R. Martin |
|
Name: |
Michael R. Martin |
|||
|
|
Title: |
Chief Operating Officer |
EXHIBIT INDEX
Exhibit |
Description of Exhibit |
|
99.1 |
News Release – Aurinia Pharmaceuticals to Present at the 2015 Rodman & Renshaw 17th Annual Global Investment Conference |
3
Exhibit 99.1
Aurinia Pharmaceuticals to Present at the 2015 Rodman & Renshaw 17th Annual Global Investment Conference
VICTORIA, British Columbia--(BUSINESS WIRE)--September 2, 2015--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH; TSX:AUP) today announced that its President and Chief Executive Officer, Stephen W. Zaruby, will present a corporate overview of the Company at the 2015 Rodman & Renshaw 17th Annual Global Investment Conference, taking place September 8th – 10th, 2015 in New York at The St. Regis Hotel.
Aurinia Presentation Details
Date: | Wednesday, September 9th, 2015 | ||
Time: | 10:25 a.m. Eastern time | ||
Location: | New York, The St. Regis Hotel – Louis XVI A Room | ||
Webcast: |
http://www.wsw.com/webcast/rrshq25/auph |
||
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently in the recruitment and enrollment phase of its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com for more information.
CONTACT:
Aurinia Pharmaceuticals Inc.
Stephen W. Zaruby,
250-708-4293
President & Chief Executive Officer
szaruby@auriniapharma.com
or
Investors
& Media:
Michael R. Martin, 250-708-4272
Chief Operating
Officer
mmartin@auriniapharma.com